Cardinal Plans Geographic, Services Expansion In China As Massive Consolidation Steams Ahead
This article was originally published in PharmAsia News
Cardinal is entering new fields, including direct-to-patient distribution, as it tries to differentiate itself from local Chinese distributors.
You may also be interested in...
Cardinal Health's Acquisition Of Zuellig Pharma Signal Of China's Intent To Allow More Foreign Investment?
Prices of direct acting hepatitis C drugs are down by 85% in China, with cancer and antidiabetes therapy costs cut by 65% and drug makers are rushing to celebrate. Scrip delves into the considerations behind the low prices and whether industry's excitement is a bit premature.